Madrigal Pharmaceuticals (NASDAQ: MDGL)
$412.23
(-0.6%)
-$2.45
Price as of August 25, 2025, 4:00 p.m. ET
Madrigal Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Madrigal Pharmaceuticals Company Info
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
News & Analysis
The Fool has written over 100 articles on Madrigal Pharmaceuticals.
Featured Article
Madrigal (MDGL) Q2 Revenue Soars 1,313%
Motley Fool Markets Team | Aug 5, 2025
Featured Article
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Keith Speights | Feb 26, 2025
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
Eric Volkman | Jan 17, 2025
Why Madrigal Pharmaceuticals Stock Is Sinking Today
Keith Speights | Jan 13, 2025
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
Alex Carchidi | Nov 23, 2024
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
Alex Carchidi | Nov 10, 2024
There's a bright future ahead for this company.
Is Madrigal Pharmaceuticals Stock a Buy?
Prosper Junior Bakiny | Aug 17, 2024
The biotech could be worth a lot more in 10 years.
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
Alex Carchidi | Aug 14, 2024
One player's minor pain is another's moderate gain.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.